PORTSMOUTH, N.H., March 29,
2024 /PRNewswire/ -- Leading diagnostic and
therapeutic medical technology company Laborie Medical Technologies
Corp. (Laborie) announced its investment in iO Urology, a
venture-backed medical technology company that developed
CarePath® an at-home, handheld uroflow device
that is FDA-approved and has been utilized in multiple urology
clinics in the U.S.
CarePath's simplistic model allows the device to be shipped
directly to the patient's home and uses embedded cellular
connectivity. This provides reliable, accurate data and improves
diagnosing and managing lower urinary tract (LUTS) issues such as
BPH (Benign Prostatic Hyperplasia). Patients see their voids and
functions first-hand and receive education about BPH and the
various treatment options available to manage the disease.
As many as 14 million men in the
United States have symptoms of BPH, and if left untreated,
BPH can lead to severe disease of the bladder and kidneys. A gap in
patient awareness and education about BPH is believed to be the
primary reason driving non-compliance and lack of engagement. Most
patients seek specialist care from a urologist, and many leave with
a prescription for oral therapy. However, just a fraction of
patients return for a follow-up visit.
With CarePath, 91% of patients returned to the clinic to review
the CarePath Uroflow report with their provider and consider
surgical intervention. Men who were educated with repetitive
measurements of urine volume flow and disease education were
significantly more likely to engage in managing the condition.
"At Laborie, we strongly believe in the value of patient
education as a pathway to support the restoration of patient
dignity," said Tim Panciera, Vice
President and General Manager of Laborie's Urology Business Unit.
"The team at iO Urology developed a state-of-the-art device with a
dynamic patient ecosystem that empowers patient engagement as a
superior standard of care. Our missions are closely aligned, making
this a natural investment to continue accelerating Laborie's
position and expertise in the advanced diagnostics market."
"We're eager to collaborate with Laborie, pioneers in diagnostic
and therapeutic urologic healthcare," said iO Urology Co-Founder
and CEO Britton Garrett. "CarePath
bridges the clinic-patient gap, offering a convenient, accessible
solution for managing urological conditions in the home."
About Laborie Medical Technologies
Headquartered in Portsmouth, New
Hampshire, Laborie is a global medical technology company
focused on Urology, Urogynecology, Gastroenterology, Obstetrics,
Gynecology & Neonatal Health. We manufacture and deliver
high-quality, high-impact diagnostic and therapeutic products that
help clinicians and hospitals preserve and restore patient dignity.
Clinicians and hospitals look to us as the market-leading experts
in our business segments, and we support our products with a
world-class clinical education & information program. Laborie
is a portfolio company of Patricia Industries. For more information
visit www.laborie.com.
View original
content:https://www.prnewswire.com/news-releases/laborie-medical-technologies-invests-in-io-urology-and-the-carepath-uroflow-device-302103599.html
SOURCE Laborie Medical Technologies